A
new review of
malaria vaccine trials has found one kind of vaccine that holds
real promise for combating this ancient disease. Epidemiologist
Patricia Graves examined a collection of previously published
studies to analyze which of the vaccines being tested in humans
works best.
In one study,
an experimental vaccine called RTS,S was given to men in The Gambia.
The men got a booster shot one year later. The Gambian men had about
a 65 percent reduction in malaria attacks after both doses. Graves
looked at another trial of the same vaccine with 5 to 9 year olds in
Mozambique, and reports, "There was about a 25 percent reduction in
clinical malaria attacks in the vaccinated children. But most
importantly, there was a more than 50 percent reduction in the
number of severe malaria attacks in the vaccinated children compared
to children who received placebo." That reduction is important
because malaria is especially deadly in children.
Usually, when
scientists create vaccines, they want something that is much better
than 50 percent effective. But malaria is caused by a parasite, so
it's different than other diseases, and Graves explains that's part
of the problem with finding a vaccine. "Malaria is a much more
complicated organism than the usual things we vaccinate against,
like measles or DPT, which are [caused by] viruses, or bacteria that
[are] easier to prevent against."
Some
scientists now believe that an effective malaria vaccine will be a
combination of several vaccines, none of which is completely
effective on its own.Graves published her review as part of the
Cochrane Collaboration. The organization's volunteer researchers
synthesize results of clinical trials and published studies to come
up with clinical recommendations. Graves says it's a valuable
approach. "This is a way of presenting all the information at once,
and allowing it to be appraised comparatively. You can look at the
aggregated data that's accumulated over time and see a trend
emerging." She adds that looking at data this way also allows
researchers to focus their attention on more successful treatments
that warrant further study.